| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 75 |
| 1 | CAPECITABINE | 49 |
| 2 | FLUOROURACIL | 47 |
| 3 | FLUOROURACIL CREAM, 0.5% | 47 |
| 4 | FUROSEMIDE | 45 |
| 5 | PEMBROLIZUMAB | 45 |
| 6 | PACLITAXEL | 41 |
| 7 | OXALIPLATIN | 40 |
| 8 | CARBOPLATIN | 35 |
| 9 | PACLITAXEL (AIBUMIN-BOUND) | 35 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ADALIMUMAB-AQVH | 1 | 0.0101 |
| 1 | RELACORILANT | 1 | 0.0101 |
| 2 | ERYTHROMYCIN LACTOBIONATE | 1 | 0.0068 |
| 3 | CLINDAMYCIN PHOSPHATE AND TRETINOIN | 1 | 0.0065 |
| 4 | PRILOCAINE HYDROCHLORIDE | 1 | 0.0062 |
| 5 | ZOLBETUXIMAB | 8 | 0.0052 |
| 6 | BENZOCAINE AND DEXTROMETHORPHAN HYDROBROMIDE | 1 | 0.0040 |
| 7 | BENZOCAINE AND MENTHOL | 1 | 0.0038 |
| 8 | DIMETICONE | 1 | 0.0035 |
| 9 | L-GLUTAMINE | 1 | 0.0028 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 108 |
| 1 | Platinum-based Drug [EPC] | 100 |
| 2 | Corticosteroid [EPC] | 85 |
| 3 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 75 |
| 4 | Kinase Inhibitor [EPC] | 73 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 67 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 57 |
| 7 | Microtubule Inhibitor [EPC] | 50 |
| 8 | Loop Diuretic [EPC] | 49 |
| 9 | Proton Pump Inhibitor [EPC] | 41 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 8 | 0.0052 |
| 1 | Vasopressin Receptor Agonist [EPC] | 1 | 0.0030 |
| 2 | Interleukin-6 Antagonist [EPC] | 1 | 0.0015 |
| 3 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 4 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 9 | 0.0014 |
| 5 | Estrogen Receptor Antagonist [EPC] | 28 | 0.0007 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 67 | 0.0007 |
| 7 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 14 | 0.0007 |
| 8 | Cannabinoid [EPC] | 5 | 0.0006 |
| 9 | Histone Deacetylase Inhibitor [EPC] | 2 | 0.0005 |